Novel Antimicrobial Agents Against Multi-drug-resistant Gram-positive Bacteria: An Overview
Venetia Giannakaki and Spiros Miyakis
Pages 182-188 (7)
Antimicrobial resistance threatens to compromise the treatment of bacterial infectious diseases. Strains resistant
to most (if not all) antibiotics available have emerged. Gram-positive such representatives include strains of Methicillinresistant
Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE) and highly-resistant to penicillin
Streptococcus pneumoniae. Although the phenomenon of antimicrobial drug resistance is expanding, limited number of
new antibiotics has been successfully developed in the last few decades. Several novel antimicrobial agents, however, are
currently in diverse phases of development and undergoing clinical trials. This review will summarize the main candidates
for novel antibacterial agents active against Gram-positive multi-resistant pathogens along with the discussion of some
patents relevant to the topic.
Antimicrobials, multidrug resistance, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, penicillin-resistant Streptococcus pneumoniae, clinical trial, Glycopeptide-related Derivatives, Oritavancin, Carbapenems, Fluorocyclines
The Academic Suite, Level 8, Block C, The Wollongong Hospital, Wollongong NSW 2500, Australia.